1478-3231/asset/LIV_left.gif?v=1&s=85fae709761c931e1b1f055c02ebb481958f0f73)
The role of triple therapy in HCV genotype 1-experienced patients
Article first published online: 4 JAN 2011
DOI: 10.1111/j.1478-3231.2010.02410.x
© 2011 John Wiley & Sons A/S
Issue
Liver International
Special Issue: Proceedings of the 4th Paris Hepatitis Conference. The publication of this supplement was supported by an unrestricted educational grant from F. Hoffmann-Laroche Ltd.
Volume 31, Issue Supplement s1, pages 58–61, January 2011
Additional Information
How to Cite
Fried, M. W. (2011), The role of triple therapy in HCV genotype 1-experienced patients. Liver International, 31: 58–61. doi: 10.1111/j.1478-3231.2010.02410.x
Publication History
- Issue published online: 4 JAN 2011
- Article first published online: 4 JAN 2011
- Received 10 November 2010Accepted 8 December 2010
- Abstract
- Article
- References
- Cited By
Keywords:
- boceprevir;
- hepatitis C;
- non-responder;
- peginterferon;
- relapser;
- telaprevir
Abstract
The ability to achieve a sustained virological response (SVR) to peginterferon (PEG-IFN) and ribavirin (RBV) depends on numerous host and virological factors, as well as adherence to a prescribed treatment regimen. Patients who have failed to achieve a SVR to PEG-IFN and RBV have limited options for retreatment. Emerging data from phase II and phase III clinical trials of direct-acting antiviral agents suggest that new therapeutic regimens will be available for many patients. Treatment with protease inhibitors such as PEG-IFN, RBV, ribavirin. and boceprevir, combined with PEG-IFN and RBV, has been shown to produce high rates of virological response in both prior relapsers and, to a lesser extent, prior non-responders. The benefits of these novel treatment regimens for each individual patient must be weighed against the side effects, costs and potential of developing viral resistance. Regulatory approval of telaprevir and boceprevir is expected to begin in mid-late 2011.